Skip to main content
SpringerLink
Log in

Unanswered questions in the adjuvant therapy of breast cancer

  • Chapter
Adjuvant Therapy of Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 60))

  • 70 Accesses

Abstract

The value of adjuvant chemotherapy and endocrine therapy in the treatment of women with operable breast cancer has been a topic of controversy since the early trials of adjuvant perioperative chemotherapy of the National Surgical Adjuvant Breast Project (NSABP) and the Scandiavian Adjuvant Chemotherapy Study Group [1,2]. Over this period clinical trial methodology has evolved, providing a better understanding of how to conduct studies to more confidently and precisely answer questions of clinical importance. Randomized trials are not necessary to test the efficacy of a treatment that is uniformly curative. The recognition that small differences in treatment effect can be important necessitates comparative studies. That such studies require attention to methodologic issues with sample sizes sufficiently large to detect modest differences between two or more treatments has been generally accepted and put into practice in recent years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher B, Ravdin RG, Ausman RK, et al. Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337–356, 1968.

    Article  PubMed  CAS  Google Scholar 

  2. Nissen-Meyer R, Kjellgren K, Malmio K, et al. Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 39:2875–2882, 1978.

    Google Scholar 

  3. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005–1018, 1990.

    PubMed  CAS  Google Scholar 

  4. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor negative tumors. N Engl J Med 320:473–478, 1989.

    Article  PubMed  CAS  Google Scholar 

  5. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320:479–484, 1989.

    Article  PubMed  CAS  Google Scholar 

  6. Mansour EG, Gray R, Shatila AN, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study. N Engl J Med 320:485–490, 1989.

    Article  PubMed  CAS  Google Scholar 

  7. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491–496, 1989.

    Article  Google Scholar 

  8. Anonymous. NIH Consensus Conference: Treatment of Early-Stage Breast Cancer. JAMA 265:391–395, 1991.

    Article  Google Scholar 

  9. National Surgical Adjuvant Breast and Bowel Project B-18. A ‘unified’ trial to compare short, intensive preoperative systemic adriamycin-cyclophosphamide therapy with similar therapy administered in conventional postoperative fashion.

    Google Scholar 

  10. National Cancer Institute Clinical Oncology Program Protocol 90-C-44A. Effect of preoperative chemotherapy on axillary lymph node metastases in stage II breast cancer: A prospective randomized trial.

    Google Scholar 

  11. Ragaz J. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 56:719–724, 1985.

    Article  PubMed  CAS  Google Scholar 

  12. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319:677–683, 1988.

    Article  Google Scholar 

  13. Norton L and Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163–169, 1986.

    PubMed  CAS  Google Scholar 

  14. Goldie JH and Coldman AJ. A mathematical model for relating drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.

    PubMed  CAS  Google Scholar 

  15. Fisher B, Gunduz A, and Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488–1492, 1982.

    Google Scholar 

  16. Simpson-Herren L, Sanford AH, and Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 60:1749–1760, 1976.

    PubMed  CAS  Google Scholar 

  17. Nissen-Meyer R, Host H, Kjellgren K, et al. Treatment of node-negative breast cancer patients with short course of chemotherapy immediately after surgery. NCI Monogr 1: 125–128, 1986.

    PubMed  Google Scholar 

  18. Jones SE, Brooks RR, Takasugi BJ, et al. Current results of the University of Arizona adjuvant breast cancer trials (1974–1978). Rec Results Cancer Res 96:133–141, 1985.

    Article  Google Scholar 

  19. Buzdar AU, Smith TL, Powell KC, et al. Effect of timing of initiation of adjuvant chemotherapy on disease free survival in breast cancer. Breast Cancer Res Treat 2:163–169, 1982.

    Article  PubMed  CAS  Google Scholar 

  20. Glucksberg H, Rivkin SE, Rasmussen S, et al. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. A Southwest Oncology Group Study. Cancer 50:423–434, 1982.

    Article  PubMed  CAS  Google Scholar 

  21. Southwest Oncology Group Protocol 8313. Multiple drug adjuvant chemotherapy for patients with ER negative Stage II carcinoma of the breast.

    Google Scholar 

  22. Southeastern Cancer Study Group Protocol 83-307. Phase III comparison of cyclophosphamide, doxorubicin, and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil both given to maximal tolerated dosage as adjuvant therapy after mastectomy or tylectomy-and-irradiation for carcinoma of the breast with positive axillary nodes.

    Google Scholar 

  23. National Cancer Institute of Canada Protocol MA.5. Cooperative clinical trial of intensive CEF versus standard CMF as adjuvant therapy for breast carcinoma in premenopausal women with histologically involved axillary nodes.

    Google Scholar 

  24. Intergroup Protocol-0102. Phase III comparison of adjuvant chemotherapy with or without endocrine therapy in high-risk, node negative breast cancer patients, and a natural history follow up study in low-risk node negative patients.

    Google Scholar 

  25. Wickerham D, Fisher B, Brown A, et al. Two months of dotorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosplamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483–1494, 1990.

    PubMed  Google Scholar 

  26. Fisher B, Redmond C, Fisher ER, et al. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. NCI Monogr 1:35–43, 1986.

    PubMed  Google Scholar 

  27. Swain S, Lippman ME, Egan EF, et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890–899, 1989.

    PubMed  CAS  Google Scholar 

  28. North Central Cancer Treatment Group protocol 89-32-51. Dose-intensification of CFP regimen followed by integration of leucovorin: A dose-seeking trial in women with metastatic breast cancer.

    Google Scholar 

  29. Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6, 1981.

    Article  PubMed  CAS  Google Scholar 

  30. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4:459–471, 1986.

    PubMed  CAS  Google Scholar 

  31. Goldenberg GJ and Froese EK. Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34: 763–770, 1985.

    Article  PubMed  CAS  Google Scholar 

  32. Osborne CK, Kitten L, and Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:710–717, 1989.

    PubMed  CAS  Google Scholar 

  33. Intergroup-0100 (ECOG, SWOG, NCCTG). Phase III comparison of adjuvant chemoendocrine therapy with CAF and concurrent or delayed tamoxifen to tamoxifen alone in postmenopausal patients with involved axillary lymph nodes and positive receptors.

    Google Scholar 

  34. International Breast Cancer Study Group protocol VII. Adjuvant therapy in node positive and high-risk node negative patients with operable breast cancer.

    Google Scholar 

  35. NSABP B-20. A clinical trial to determine the worth of chemotherapy and tamoxifen over tamoxifen alone in the management of patients with primary invasive breast cancer, negative axillary nodes and estrogen-receptor-positive tumors.

    Google Scholar 

  36. NCIC MA.4. National Cancer Institute of Canada cooperative clinical trial of adjuvant postsurgical treatment of breast carcinoma in postmenopausal patients with histologically involved axillary nodes. A joint study of the Toronto-Edmonton Breast Study Group and the NCIC Clinical Trials Group.

    Google Scholar 

  37. Intergroup-0101 (ECOG, SWOG). Phase III comparison of combination chemotherapy (CAF) and chemohormonal therapy (CAF + zoladex or CAF + zoladex + tamoxifen) in premenopausal women with axillary node-positive breast cancer.

    Google Scholar 

  38. Scottish Clinical Trials Committee Trial A. A randomized comparison of chemotherapy (CMF) versus bilateral oophorectomy with or without prednisone in premenopausal women with operable, node positive breast cancer.

    Google Scholar 

  39. Bonadonna G and Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15, 1981.

    Article  PubMed  CAS  Google Scholar 

  40. Hryniuk W and Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer. J Clin Oncol 4:1162–1170, 1986.

    PubMed  CAS  Google Scholar 

  41. Henderson IC, Hayes DF, and Gelman R. Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501–1515, 1988.

    PubMed  CAS  Google Scholar 

  42. CALGB 8541 — Adjuvant CAF for pathologic stage II, node-positive breast cancer: Randomization among intensive CAF for four cycles vs low CAF for four cycles vs standard dose CAF for six cycles.

    Google Scholar 

  43. Budman DA, Wood W, Henderson IC, et al. Initial Findings of CALGB 8541: A Dose and Dose Intensity trial of Cyelophosphomide (C), Doxorubicine (A), and 5 Fluorouracil (F) as Adjuvant Treatment of Stage II, Node and Breast Cancer. ASCO May 29, 1992.

    Google Scholar 

  44. NSABP B-22. A clinical trial to evaluate dose intensification and increased cumulative dose on disease-free survival and survival of primary breast cancer patients with positive axillary nodes receiving postoperative Adriamycin-cyclophosphamide (AC) therapy.

    Google Scholar 

  45. Beveridge RA, Abeloff MD, Donehower RC, et al. Sixteen week dose intense chemotherapy for breast cancer. Proc Am Soc Clin Oncol 7:13, 1988.

    Google Scholar 

  46. Intergroup-0108 (ECOG, SWOG). Phase III comparison of cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) and a 16-week multi-drug regimen as adjuvant therapy for patients with hormone receptor negative, node-positive breast cancer.

    Google Scholar 

  47. Santos GW. Overview of autologous bone marrow transplantation. Int J Cell Cloning 3:215–216, 1985.

    Google Scholar 

  48. Peters WP, Shpall EJ, Jones RB, and Ross M. High-dose combination cyclophosphamide, cisplatin and carmustine with bone marrow support as initial treatment for metastatic breast cancer: Three-six year follow up. Proc Am Soc Clin Oncol 9:10, 1990.

    Google Scholar 

  49. Eder JP, Antman K, Elias A, et al. High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic disease. J Clin Oncol 4:1592–1597, 1986.

    PubMed  CAS  Google Scholar 

  50. Jones RB, Shpall EJ, Ross M, et al. AFM induction chemotherapy, followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer. Current results. Proc Am Soc Clin Oncol 9:9, 1990.

    Google Scholar 

  51. Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207–1216, 1990.

    PubMed  CAS  Google Scholar 

  52. Kennedy MJ, Beveridge R, Rowley S, et al. High dose consolidation chemotherapy and rescue with purged autologous bone marrow following dose-intense induction for metastatic breast cancer. Proc Am Soc Clin Oncol 8:19, 1989.

    Google Scholar 

  53. Dana Farber Cancer Institute Protocol 88-024. STAMP V intensification for metastatic breast cancer responsive to standard dose chemotherapy.

    Google Scholar 

  54. Antman K, Bearman SI, Davidson N, et al. High dose therapy in breast cancer with autologous bone marrow support: Current status. J Clin Oncol, in press.

    Google Scholar 

  55. Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group Phase III study. J Clin Oncol 8:599–607, 1990.

    PubMed  CAS  Google Scholar 

  56. EST-5181. Adjuvant therapy for premenopausal women with operable node positive breast cancer: An Eastern Cooperative Oncology Group study.

    Google Scholar 

  57. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis of eight years by Nolvadex Adjuvant Trial Organisation. Br J Cancer 57:608–611, 1988.

    Google Scholar 

  58. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial: Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171–175, 1987.

    Google Scholar 

  59. Ribeiro G and Swindell R. The Christie Hospital tamoxifen adjuvant trial for operable breast cancer — Status at 10 years. Br J Cancer 57:601–603, 1988.

    Article  PubMed  CAS  Google Scholar 

  60. Mouridsen HT, Andersen AP, Brincker H, et al. Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: Present status of Danish Breast Cancer Cooperative Group trials. NCI Monogr 1:115–118, 1986.

    PubMed  Google Scholar 

  61. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681–1692, 1988.

    Article  Google Scholar 

  62. Fisher B, Brown A, Wolmark N, et al. Prolonging tamoxifen therapy for primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106:649–654, 1987.

    PubMed  CAS  Google Scholar 

  63. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126–131, 1989.

    Article  PubMed  CAS  Google Scholar 

  64. Henderson IC, Gelman RS, Harris JR, and Canellos GP. Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1:95–98, 1986.

    PubMed  Google Scholar 

  65. Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2–10, 1983.

    PubMed  CAS  Google Scholar 

  66. Rivkin S, Knight WA, McDivitt R, et al. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. World J Surg 9:723–727, 1985.

    Article  PubMed  CAS  Google Scholar 

  67. Levine MN, Gent M, Hryniuk WM, et al. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 8:1217–1225, 1990.

    PubMed  CAS  Google Scholar 

  68. Osborne CK. Prognostic factors in breast cancer. In: Principles & Practice of Oncology, Vol. 4. VT Devita, S Hellman, and SA Rosenberg (eds). 1990, pp. 1–11.

    Google Scholar 

  69. Rosen PP, Groshen S, Saigo PE, et al. Pathologic prognostic factos in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239–1251, 1989.

    PubMed  CAS  Google Scholar 

  70. Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076–1087, 1988.

    PubMed  CAS  Google Scholar 

  71. O’Reilly SM, Camplejohn RS, Barnes DM, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 61:671–674, 1990.

    Article  PubMed  Google Scholar 

  72. Clark GM, Dressler LG, Owens MA, et al. Prediction of relapse of survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627–633, 1989.

    Article  PubMed  CAS  Google Scholar 

  73. Kallioniemi OP, Blanco G, Alavaikko M, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. Cancer 62:2183–2190, 1988.

    Article  PubMed  CAS  Google Scholar 

  74. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707–712, 1989.

    Article  PubMed  CAS  Google Scholar 

  75. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297–302, 1990.

    Article  PubMed  CAS  Google Scholar 

  76. McGuire WL, Tandon AK, Allred DC, and Chamness, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Nat Cancer Inst 82:1006–1015, 1990.

    Article  PubMed  CAS  Google Scholar 

  77. National Surgical Adjuvant Breast Project Protocl B-19. A clinical trial to compare sequential methotrexate, 5-fluorouracil (M → F) with conventional CMF in primary breast cancer patients with negative nodes and estrogen-receptor-negative tumors.

    Google Scholar 

Download references

Authors
  1. F. Andrew Dorr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, San Francisco, USA

    I. Craig Henderson

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dorr, F.A., Friedman, M.A. (1992). Unanswered questions in the adjuvant therapy of breast cancer. In: Henderson, I.C. (eds) Adjuvant Therapy of Breast Cancer. Cancer Treatment and Research, vol 60. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3496-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3496-9_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6550-1

  • Online ISBN: 978-1-4615-3496-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation